Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bolaget.

Datum Källa Rubrik Typ Alternativ
2023-01-17 Lipidor Kommuniké från extra bolagsstämma i Lipidor AB (publ) Analyser Ladda ner | Visa Stäng
2023-01-17 Lipidor Bulletin from the extraordinary general meeting of Lipidor AB (publ) Analyser Ladda ner | Visa Stäng
2022-12-23 Lipidor NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL) Analyser Ladda ner | Visa Stäng
2022-12-23 Lipidor KALLELSE TILL EXTRA BOLAGSSTÄMMA I LIPIDOR AB (PUBL) Analyser Ladda ner | Visa Stäng
2022-12-23 Lipidor Styrelsen i Lipidor beslutar om att kalla till extra bolagsstämma för godkännande av försäljning av dotterbolagsaktier till större ägare Analyser Ladda ner | Visa Stäng
2022-12-23 Lipidor The Board of Lipidor resolves to summon an Extraordinary General Meeting for approval of the sale of subsidiary shares to major owners Analyser Ladda ner | Visa Stäng
2022-12-14 Lipidor Lipidor secures bridge financing of at least SEK 5 million through loans and subsidiary share sales, and takes cost-saving measures including staff layoffs Analyser Ladda ner | Visa Stäng
2022-12-14 Lipidor Lipidor säkrar bryggfinansiering om minst 5 MSEK genom lån och försäljning av dotterbolagsaktier samt vidtar åtgärder för kostnadsbesparing inklusive uppsägningar av personal Analyser Ladda ner | Visa Stäng
2022-12-08 Lipidor Lipidor presents Nomination Committee Analyser Ladda ner | Visa Stäng
2022-12-08 Lipidor Lipidor presenterar valberedningen Analyser Ladda ner | Visa Stäng
2022-11-23 Lipidor Lipidor AB (publ) offentliggör delårsrapport för tredje kvartalet 2022 Analyser Ladda ner | Visa Stäng
2022-11-23 Lipidor Lipidor AB (publ) publishes interim report for third quarter 2022 Analyser Ladda ner | Visa Stäng
2022-11-15 Lipidor Lipidor lämnar uppdatering efter utfall av Fas III-studien med psoriasiskandidaten AKP02 Analyser Ladda ner | Visa Stäng
2022-11-15 Lipidor Lipidor provides update following outcome of Phase III study of psoriasis candidate AKP02 Analyser Ladda ner | Visa Stäng
2022-10-28 Lipidor Lipidor meddelar resultat från bolagets kliniska Fas III-studie av AKP02 mot psoriasis Analyser Ladda ner | Visa Stäng
2022-10-28 Lipidor Lipidor announces results from the company's clinical Phase III study of AKP02 for psoriasis Analyser Ladda ner | Visa Stäng
2022-10-07 Lipidor Emollivet når milstolpe med över 1000 sålda produkter och förbereder nu för uppskalad produktion Analyser Ladda ner | Visa Stäng
2022-10-07 Lipidor Emollivet reaches milestone of over 1,000 products sold and prepares for scaled-up production Analyser Ladda ner | Visa Stäng
Analyser | 7 Oct 2022 | Lipidor

Emollivet reaches milestone of over 1,000 products sold and prepares for scaled-up production

GOTHENBURG, Sweden, 7th October 2022 – Earlier this year, Lipidor’s subsidiary Emollivet launched Emollivet COMBI – an antiseptic emollient spray for horses with pastern dermatitis. The product has generated great interest among horse owners, and recently the milestone of 1,000 products sold was reached. The company is now preparing for scaled-up production to meet the high demand.

Emollivet’s goal is to make everyday life easier for all pet owners whose animals suffer from skin problems. Equine pastern dermatitis – commonly known as scratches and mud fever – is one of the most common skin conditions that horse owners wrestle with in their everyday lives, and so this spring Emollivet launched Emollivet COMBI, a user-friendly spray that makes it easy for owners to take care of their horse’s skin problems every day, giving owners more quality time with their horse.

Since the product launch on March 3rd earlier this year, sales have picked up speed, and now Emollivet can announce that the milestone of 1000 products sold has been reached. The company is now preparing for scaled-up production to be able to meet the high demand.

”We are overwhelmed by the response that COMBI has received in the market. The great interest from horse owners shows that we’re solving a real problem for them. The feedback we receive from customers plays a central role in our continued journey towards building a long-term sustainable growth company” says Stina Linge, CEO of Emollivet.

In connection with the launch of COMBI, Emollivet closed a funding round for the purposes of marketing COMBI and accelerating the development of more products for pet owners whose animals suffer from skin problems. Linge continues:

”One of the goals of the round was to sell 1,000 products and it feels great to have already achieved this. In addition to continued scaling up of COMBI, we are now working towards the launch of Emollivet’s second product later this year.”

2022-09-29 Lipidor Lipidor updates on Phase III clinical study of psoriasis candidate AKP02 Analyser Ladda ner | Visa Stäng
2022-09-29 Lipidor Lipidor uppdaterar om sin kliniska Fas III-studie med psoriasiskandidaten AKP02 Analyser Ladda ner | Visa Stäng
2022-08-25 Lipidor Lipidor appoints new CFO Charlotta Ekman Analyser Ladda ner | Visa Stäng
2022-08-25 Lipidor Lipidor utser Charlotta Ekman som ny Chief Financial Officer Analyser Ladda ner | Visa Stäng
2022-08-24 Lipidor Lipidor AB (publ) offentliggör delårsrapport för andra kvartalet 2022 Analyser Ladda ner | Visa Stäng
2022-08-24 Lipidor Lipidor AB (publ) publishes interim report for second quarter 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Lipidor Samtliga patienter i Lipidors Fas III-studie med psoriasiskandidaten AKP02 är färdigbehandlade Analyser Ladda ner | Visa Stäng
2022-08-23 Lipidor All patients in Lipidor's Phase III study with psoriasis candidate AKP02 have completed treatment Analyser Ladda ner | Visa Stäng
2022-07-11 Lipidor Lipidor's Phase III study of AKP02 for treatment of psoriasis now fully recruited, results expected Q3 2022 Analyser Ladda ner | Visa Stäng
2022-07-11 Lipidor Lipidors Fas III-studie med AKP02 för behandling av psoriasis är fullrekryterad, resultat väntas under Q3 2022 Analyser Ladda ner | Visa Stäng
2022-06-02 Lipidor Bulletin from the annual general meeting of Lipidor AB (publ) Analyser Ladda ner | Visa Stäng
2022-06-02 Lipidor Kommuniké från årsstämma i Lipidor AB (publ) Analyser Ladda ner | Visa Stäng
2022-05-20 Lipidor Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited Pressreleaser Ladda ner | Visa Stäng
2022-05-20 Lipidor Lipidor uppdaterar om Fas III-studien med AKP02 för behandling av psoriasis - hälften av patienterna rekryterade Pressreleaser Ladda ner | Visa Stäng
2022-05-05 Lipidor Lipidor AB (publ) publishes interim report for first quarter 2022 Rapporter Ladda ner | Visa Stäng
2022-05-05 Lipidor Lipidor AB (publ) offentliggör delårsrapport för första kvartalet 2022 Rapporter Ladda ner | Visa Stäng
2022-05-03 Lipidor Lipidor: KALLELSE TILL ÅRSSTÄMMA I LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-05-03 Lipidor Lipidor: NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-04-28 Lipidor Lipidor AB (publ) publishes annual report for 2021 Rapporter Ladda ner | Visa Stäng
2022-04-28 Lipidor Lipidor AB (publ) offentliggör årsredovisning för 2021 Rapporter Ladda ner | Visa Stäng

Kommande händelser

22 Feb 2023 | Bokslutskommuniké 2022
11 May 2023 | Kvartalsrapport 2023-Q1
23 Aug 2023 | Kvartalsrapport 2023-Q2
22 Nov 2023 | Kvartalsrapport 2023-Q3